Skip to content
Screener

Alkermes ALKS Vivitrol — Revenue

Other product segments

Aristada And Aristada Initio
$96.72M—
LUMRYZ
$96.57M—
LYBALVI
$93.98M—

Similar metrics at other companies

HRO
HROWOther Revenues — Revenue
$73K-15.1%
Oracle logo
ORCLCloud Revenues — Revenue
$9.91B+47.1%
Oracle logo
ORCLSoftware Revenues — Revenue
$6.82B-2.1%
Blue Owl Capital logo
OWLPerformance revenues — Revenue
$6.07M-3.9%
EAT
EATFranchise revenues — Revenue
$14.7M+21.5%
Cinemark Holdings logo
CNKOther Revenues — Revenue
$113.1M+18.2%

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.32B+89.9%
Enterprise value$9.38B+139%
P/E125.9×+113×
P/S5×+2.1×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
(In thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
VIVITROL$124,454$121,660$236,888$222,656
ARISTADA and ARISTADA INITIO96,719101,295190,543174,770
LYBALVI93,97984,280186,343154,302
LUMRYZ96,572—136,064—
Total product sales, net$411,724$307,235$749,838$551,728

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's vivitrol — revenue?
Alkermes (ALKS) reported vivitrol — revenue of $124.45M in Q2 2026.
How has Alkermes's vivitrol — revenue changed year-over-year?
Alkermes's vivitrol — revenue increased by 2.3% year-over-year, from $121.66M to $124.45M.
What is the long-term trend for Alkermes's vivitrol — revenue?
Over 4 years (2021 to 2025), Alkermes's vivitrol — revenue has grown at a 8.0% compound annual growth rate (CAGR), from $343.85M to $467.91M.
What does vivitrol — revenue mean?
This metric represents the total net revenue generated from the sale of a specific pharmaceutical product after adjusting for variable considerations such as rebates, discounts, and returns. It reflects the core commercial performance and market adoption of the product within the company's portfolio. By excluding assessed taxes, it provides a clean view of the underlying economic value derived from customer contracts.

Ask your AI about Alkermes's vivitrol — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude